Adam Gault BofA downgraded Omnicell ( NASDAQ: OMCL ) to neutral from buy, commenting that product revenue growth “may be elusive” in 2025-2026. BofA said that while product extensions like XTAmplify can help drive sales, it believes visibility into the company’s growth is low, noting that no.
Back to Health Page
